These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1023 related articles for article (PubMed ID: 11726007)

  • 1. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.
    Roach P; Yue L; Arora V
    Diabetes Care; 1999 Aug; 22(8):1258-61. PubMed ID: 10480767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus.
    Roach P; Arora V; Campaigne BN; Mattoo V; Rangwala S;
    Diabetes Obes Metab; 2003 Sep; 5(5):311-6. PubMed ID: 12940868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
    Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
    Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
    Herz M; Arora V; Campaigne BN; Scholtz HE; Potgieter MA; Mollentze W
    S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan.
    Mattoo V; Milicevic Z; Malone JK; Schwarzenhofer M; Ekangaki A; Levitt LK; Liong LH; Rais N; Tounsi H;
    Diabetes Res Clin Pract; 2003 Feb; 59(2):137-43. PubMed ID: 12560163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes.
    Herz M; Profozic V; Arora V; Smircic-Duvnjak L; Kovacevic I; Boras J; Campaigne BN; Metelko Z
    Curr Med Res Opin; 2002; 18(4):188-93. PubMed ID: 12201618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?
    Malone JK; Beattie SD; Campaigne BN; Johnson PA; Howard AS; Milicevic Z
    Diabetes Res Clin Pract; 2003 Dec; 62(3):187-95. PubMed ID: 14625133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.
    Malone JK; Yang H; Woodworth JR; Huang J; Campaigne BN; Halle JP; Yale JF; Grossman LD
    Diabetes Metab; 2000 Dec; 26(6):481-7. PubMed ID: 11173719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.
    Coscelli C; Iacobellis G; Calderini C; Carleo R; Gobbo M; Di Mario U; Leonetti F; Galluzzo A; Pirrone V; Lunetta M; Casale P; Paleari F; Falcelli C; Valle D; Camporeale A; Merante D
    Acta Diabetol; 2003 Dec; 40(4):187-92. PubMed ID: 14740279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
    Koivisto VA; Tuominen JA; Ebeling P
    Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.